Skip to main
TECH
TECH logo

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 38%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne has demonstrated robust financial performance, reporting a 9% organic growth in FQ2'25, which contributed to a revenue beat of approximately 4%, largely driven by increased spending in the pharmaceutical and biotech sectors. The company’s segmented growth was notable, with the Protein Sciences segment seeing an 8% year-over-year organic increase, while the Diagnostics and Spatial Biology segment experienced a 12% organic growth, reflecting strong demand across various applications. Furthermore, strategic shifts made under previous leadership and favorable market conditions are expected to support continued growth, positioning Bio-Techne favorably for consistent double-digit revenue growth and potential margin expansion in the future.

Bears say

Bio-Techne faces potential risks to its revenue and earnings estimates due to anticipated lower demand for its current and future product offerings, which could result in revenue declines particularly in the smaller biotech purchasing segment. The company is also experiencing elevated inventories and reduced equipment sales as a consequence of supply chain disruptions from the pandemic, compounded by a slowdown in growth comparable to larger industry competitors. Furthermore, prolonged macroeconomic challenges affecting end markets for life science tools and diagnostics, as well as increasing competition from larger firms, raise concerns about the company’s ability to meet future industry demand and achieve consistent revenue growth.

Bio-Techne (TECH) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 38% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 21 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $160.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $160.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.